Delayed order intake for automated nucleic acid extraction systems
First written in FY2018-Q1. 6 of 14 entries say "Mitigated", first in FY2019-Q2. Latest entry: FY2024-Q1.
No other company in this theme has enough history to compare yet.
- FY2024-Q1MitigatedAnnual report
「The biomedical business posted higher revenue as overseas sales of mixing and degassing equipment and other products performed well,」
In the biomedical segment, overseas sales of mixing and degassing equipment performed well and drove higher revenue, separately from the antibody test reagent kit, for which declining sales had previously been reported. - FY2022-Q3RestatedAnnual report
「The biomedical business's mixing and degassing equipment performed well, but sales of the COVID-19 antibody test reagent kit declined.」
In the biomedical business, some products performed well, while the decline in antibody test reagent kit sales continues. - FY2022-Q2Services remain strong; antibody test kit sales declineAnnual report
「Contract gene analysis services related to the biomedical business remained strong, but sales of the COVID-19 antibody test reagent kit declined.」
In the biomedical business, contract gene analysis services remained strong, while sales of the antibody test reagent kit declined. - FY2021-Q3MitigatedAnnual report
「The biomedical segment posted higher revenue, with the COVID-19 antibody test reagent kit launched in March 2020 performing well and contract gene analysis services also remaining strong.」
The previously sluggish biomedical segment posted higher revenue as the antibody test reagent kit and contract gene analysis services performed well. - FY2021-Q1AdvancedAnnual report
「The biomedical field reported higher revenue as automated nucleic acid extraction systems performed solidly and the new coronavirus antibody test reagent kit, which began sales in March 2020, also performed well.」
Automated nucleic acid extraction systems, which had previously been sluggish, performed solidly, and the biomedical field reported higher revenue, also benefiting from the contribution of new products. - FY2020-Q2MitigatedAnnual report
「The biomedical field reported higher revenue as contract genetic analysis services and cell products performed solidly.」
The description changed from sluggish performance and delayed orders through the previous quarter to contract genetic analysis services and cell products performing solidly and driving higher revenue. - FY2020-Q1MitigatedAnnual report
「The biomedical field’s revenue was broadly in line with the same period of the previous year, as contract genetic analysis services and automated nucleic acid extraction systems performed solidly.」
In addition to automated nucleic acid extraction systems, which had previously been sluggish, contract genetic analysis services were also described as performing solidly, leaving revenue in the biomedical field broadly in line with the same period of the previous year. - FY2019-Q3MitigatedAnnual report
「The biomedical field reported higher revenue as automated nucleic acid extraction systems and cell products performed solidly.」
Automated nucleic acid extraction systems, which had previously been sluggish, performed solidly, and the biomedical field returned to revenue growth. - FY2019-Q2MitigatedAnnual report
「The biomedical field reported higher revenue as automated nucleic acid extraction systems performed well.」
Automated nucleic acid extraction systems, which had previously been sluggish, performed well, and the biomedical field returned to revenue growth. - FY2019-Q1ReframedAnnual report
「The biomedical field reported lower revenue as contract genetic analysis services and other offerings remained sluggish.」
The description of the factors behind lower revenue changed from delayed orders and sluggish performance of automated nucleic acid extraction systems to sluggish contract genetic analysis services and other offerings. - FY2018RestatedAnnual report
「The biomedical field reported lower revenue as automated nucleic acid extraction systems and other products remained sluggish.」
The sluggish performance of automated nucleic acid extraction systems and other products was also cited as a factor behind lower revenue in the biomedical field for the full year. - FY2018-Q3MaterialisedAnnual report
「The biomedical field reported lower revenue as automated nucleic acid extraction systems remained sluggish.」
The continued sluggish performance of automated nucleic acid extraction systems was reflected in lower revenue in the biomedical field for the nine months ended the third quarter. - FY2018-Q2MaterialisedAnnual report
「The biomedical field reported lower revenue as automated nucleic acid extraction systems remained sluggish.」
In connection with the delayed orders for automated nucleic acid extraction systems reported in the previous quarter, the systems’ sluggish performance and lower revenue in the biomedical field were reported as actual results. - FY2018-Q1First statedAnnual report
「The biomedical field reported lower revenue due to delayed orders for automated nucleic acid extraction systems and other factors.」
Delayed orders for automated nucleic acid extraction systems were cited for the first time as a factor behind lower revenue in the biomedical field.